Results 131 to 140 of about 838,442 (361)
Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion
Advanced Science, EarlyView.The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li +10 more
wiley +1 more source
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
Nature CommunicationsDespite the development of novel therapies for acute myeloid leukemia, outcomes remain poor for most patients, and therapeutic improvements are an urgent unmet need. Although treatment regimens promoting differentiation have succeeded in the treatment of
Edurne San José-Enériz +29 more
doaj +1 more source
Cell Stem Cell, 2019 Summary Acute myeloid leukemia (AML) is an aggressive clonal disorder of hematopoietic stem cells (HSCs) and primitive progenitors that blocks their myeloid differentiation, generating self-renewing leukemic stem cells (LSCs). Here, we show that the mRNA
J. Paris +26 more
semanticscholar +1 more source
Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy
Advanced Science, EarlyView.Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu +4 more
wiley +1 more source
Tumor Biology, 2017 Acute myeloid leukemia is characterized by its high biological and clinical heterogeneity, which represents an important barrier for a precise disease classification and accurate therapy.
Alberto Ponciano-Gómez +5 more
doaj +1 more source
Influence of Cytokines and Autologous Lymphokine-Activated Killer Cells on Leukemic Bone Marrow Cells and Colonies in AML [PDF]
, 2001 We have already shown that cytokine cocktails (IL-1 beta, IL-3, IL-6, SCF, GM-CSF) and/or lymphokine-activated killer (LAK) cells can reduce the amounts of clonal, CD34-positive mononuclear bone marrow cells (BM-MNC) in acute myeloid leukemia (AML).
Gerhartz, Helmut Heinrich +2 more
core +1 more source
Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis
Advanced Science, EarlyView.This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun +15 more
wiley +1 more source
Elucidating the role of the tumor suppressor Protein Phoshatase 2A in Chronic Myeloid Leukemia.
, 2010 Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases and is involved in the regulation of cell homeostasis through the negative regulation of signaling pathways initiated by protein kinases.
Neviani, Paolo
core
Characterisation of the role of KLF5 in normal haemopoiesis and acute myeloid leukaemia. [PDF]
, 2011 Krüppel-like factor 5 (KLF5) encodes a zinc finger transcription factor involved in growth, differentiation and apoptosis of a number of different tissues, and it has previously been implicated as either a tumour suppressor or oncogene in various solid ...
Diakiw, Sonya
core
Nature Medicine, 2017 N6-methyladenosine (m6A) is an abundant nucleotide modification in mRNA that is required for the differentiation of mouse embryonic stem cells. However, it remains unknown whether the m6A modification controls the differentiation of normal and/or ...
L. Vu +19 more
semanticscholar +1 more source